Frankfurt am Main, 18 May 2026 – avocado rechtsanwälte has advised Curaleaf International Holdings, Inc. (“Curaleaf”) on the acquisition of the remaining 45% of the shares in Four 20 Pharma GmbH (“Four 20 Pharma”). With the completion of the transaction, Curaleaf now fully acquires Four 20 Pharma, thereby strengthening its position as one of the leading international suppliers of medical cannabis products.

Four 20 Pharma is a German manufacturer and distributor of medical cannabis fully licensed under EU GMP and GDP standards and has an extensive distribution network in Germany as well as in selected European markets. The company is particularly renowned for its high-quality cultivation, pharmaceutical-grade processing and supply to care homes, pharmacies and research institutions.

With the full acquisition of Four 20 Pharma, Curaleaf is consolidating its vertically integrated, global supply chain. Curaleaf is pursuing an international growth strategy that combines local expertise with global reach to build one of the world’s leading international cannabis companies. Building on the success of Four 20 Pharma in Germany, the brand has already been launched in the UK and Poland; further international markets are set to follow.

The scope of the advice included, in particular, the structured implementation of the acquisition of the remaining 45% stake, corporate and transaction-related issues, as well as aspects relevant to review and notification requirements under competition and foreign trade law, including the European and German regulatory framework for the medical cannabis sector.

Further information is available here. 

Advisory team from avocado rechtsanwälte:

Curaleaf was advised on the transaction by the following team from avocado rechtsanwälte:

Dr Christian Berger – Corporate / M&A (lead)
Dr Sebastian Talarowski – Corporate / M&A
Alexander Rospert – Competition and Foreign Trade Law
Andrea C. Ziegler – Corporate / M&A

Our press release can be found here.